Kura Oncology, Inc. (NASDAQ:KURA) has received an average rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $18.30.
Several analysts have recently weighed in on KURA shares. Zacks Investment Research raised shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research note on Saturday, September 9th. Cann reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Wednesday, November 8th. Citigroup increased their price objective on shares of Kura Oncology from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. BidaskClub raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, Oppenheimer set a $18.00 price objective on shares of Kura Oncology and gave the stock a “buy” rating in a research report on Thursday, November 16th.
Kura Oncology (NASDAQ:KURA) traded down $0.15 during trading on Thursday, hitting $14.95. 209,300 shares of the stock traded hands, compared to its average volume of 223,614. Kura Oncology has a twelve month low of $5.78 and a twelve month high of $17.50. The company has a debt-to-equity ratio of 0.07, a quick ratio of 13.48 and a current ratio of 13.48. The stock has a market cap of $451.73, a PE ratio of -9.65 and a beta of 4.89.
Large investors have recently bought and sold shares of the stock. State of Wisconsin Investment Board purchased a new position in shares of Kura Oncology during the 2nd quarter worth approximately $102,000. Rhumbline Advisers acquired a new stake in Kura Oncology during the 2nd quarter worth approximately $131,000. New York State Common Retirement Fund acquired a new stake in Kura Oncology during the 2nd quarter worth approximately $142,000. OxFORD Asset Management LLP acquired a new stake in Kura Oncology during the 2nd quarter worth approximately $217,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in Kura Oncology during the 2nd quarter worth approximately $226,000. 64.26% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Brokerages Set Kura Oncology, Inc. (KURA) PT at $18.30” was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/brokerages-set-kura-oncology-inc-kura-pt-at-18-30/1811428.html.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.